207 related articles for article (PubMed ID: 25966119)
1. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
[TBL] [Abstract][Full Text] [Related]
2. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
4. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
6. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
7. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
[TBL] [Abstract][Full Text] [Related]
8. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
[TBL] [Abstract][Full Text] [Related]
9. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
10. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract][Full Text] [Related]
12. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
14. Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients.
Liu JY; Qian CY; Gao YF; Chen J; Zhou HH; Yin JY
Chin J Cancer; 2017 Jan; 36(1):12. PubMed ID: 28093084
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
16. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
17. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
[TBL] [Abstract][Full Text] [Related]
19. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
